Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pandemic flu H5 HA mRNA SD2 vaccine · 1 trial · 2 indications
Number of participants with immediate AEs
Number of participants with solicited injection site reactions
Number of participants with solicited systemic reactions
Number of participants with unsolicited AEs
Number of participants with MAAEs
Number of participants with AESIs
Number of participants with SAEs
Number of participants with out-of-range biological test results
| Arm | Type | Description |
|---|---|---|
| Group 1: Pandemic flu H5 HA mRNA SD2 vaccine (Low dose) | EXPERIMENTAL | Participants will receive two injections of low dose pandemic flu H5 HA mRNA SD2 vaccine Extension Phase: Additional participants will receive two injections 21 days apart of pandemic flu H5 HA mRNA SD2 vaccine at low dose |
| Group 2: Pandemic flu H5 HA mRNA SD2 vaccine (Medium dose) | EXPERIMENTAL | Participants will receive two injections of medium dose pandemic flu H5 HA mRNA SD2 vaccine |
| Group 3: Pandemic flu H5 HA mRNA SD2 vaccine (High dose) | EXPERIMENTAL | Participants will receive two injections of high dose pandemic flu H5 HA mRNA SD2 vaccine |
| Group 4: Placebo | PLACEBO_COMPARATOR | Participants will receive two injections of placebo Extension Phase: Additional participants will receive two injections 21 days apart of placebo |
| Name | Type | Description |
|---|---|---|
| Pandemic flu H5 HA mRNA SD2 vaccine | BIOLOGICAL | Pharmaceutical Form: Suspension in a vial Route of Administration: Intramuscular injection |
| Placebo | OTHER | Pharmaceutical Form: Liquid solution in a vial Route of Administration: Intramuscular injection |
Inclusion Criteria: * Aged 18 years or older on the day of inclusion * A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * Is of non-childbearing potential. To be considered of non-childbearing potential, a female...
Pandemic flu H5 HA mRNA SD2 vaccine is an investigational vaccine being developed for pandemic influenza immunization. It is designed to protect against pandemic influenza caused by the H5 HA strain. The vaccine is currently being studied in healthy adult participants aged 18 years and older to evaluate its safety and immunogenicity.
Pandemic flu H5 HA mRNA SD2 vaccine is being developed by Sanofi, a biopharmaceutical company traded on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in healthy adults.
Pandemic flu H5 HA mRNA SD2 vaccine is in Phase 1 clinical development. It is an investigational vaccine, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial is currently active but not recruiting participants.
Pandemic flu H5 HA mRNA SD2 vaccine is being evaluated in one Phase 1 clinical trial with the identifier NCT06907511. This randomized, double-blind, placebo-controlled study is assessing the safety and immunogenicity of the vaccine in healthy adults aged 18 years and older in the United States, with a planned enrollment of 720 participants.
Pandemic flu H5 HA mRNA SD2 vaccine is an mRNA-based vaccine that encodes the hemagglutinin (HA) protein from the H5 strain of pandemic influenza. The vaccine is designed to induce an immune response against the H5 HA antigen, potentially providing protection against pandemic influenza infection.